ImmuPharma Statistics

Total Valuation

ImmuPharma has a market cap or net worth of GBP 13.37 million. The enterprise value is 13.13 million.

Market Cap	13.37M
Enterprise Value	13.13M

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

ImmuPharma has 499.72 million shares outstanding. The number of shares has increased by 15.04% in one year.

Current Share Class	499.72M
Shares Outstanding	499.72M
Shares Change (YoY)	+15.04%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.75%
Owned by Institutions (%)	68.52%
Float	460.79M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	-24.62
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.29
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.42

Financial Position

The company has a current ratio of 0.58

Current Ratio	0.58
Quick Ratio	0.44
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-1,348.44

Financial Efficiency

Return on equity (ROE) is -967.41% and return on invested capital (ROIC) is -651.33%.

Return on Equity (ROE)	-967.41%
Return on Assets (ROA)	-90.42%
Return on Invested Capital (ROIC)	-651.33%
Return on Capital Employed (ROCE)	492.82%
Revenue Per Employee	n/a
Profits Per Employee	-413,917
Employee Count	6
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +5.76% in the last 52 weeks. The beta is 2.61, so ImmuPharma's price volatility has been higher than the market average.

Beta (5Y)	2.61
52-Week Price Change	+5.76%
50-Day Moving Average	2.82
200-Day Moving Average	2.50
Relative Strength Index (RSI)	39.97
Average Volume (20 Days)	2,058,733

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-2.68M
Pretax Income	-2.78M
Net Income	-2.48M
EBITDA	-2.61M
EBIT	-2.68M
Earnings Per Share (EPS)	-0.01

Full Income Statement

Balance Sheet

The company has 236,902 in cash and n/a in debt, giving a net cash position of 236,902 or 0.00 per share.

Cash & Cash Equivalents	236,902
Total Debt	n/a
Net Cash	236,902
Net Cash Per Share	0.00
Equity (Book Value)	-542,859
Book Value Per Share	-0.00
Working Capital	-635,002

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -1.77 million and capital expenditures -1,652, giving a free cash flow of -1.77 million.

Operating Cash Flow	-1.77M
Capital Expenditures	-1,652
Free Cash Flow	-1.77M
FCF Per Share	-0.00

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

ImmuPharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-15.04%
Shareholder Yield	n/a
Earnings Yield	-18.58%
FCF Yield	-13.25%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	n/a